Matinas Biopharma (NYSEAMERICAN:MTNB) Shares Up 0.4% – Here’s What Happened
by Kim Johansen · The Markets DailyMatinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report)’s stock price traded up 0.4% during trading on Friday . The company traded as high as $0.25 and last traded at $0.2340. 2,402,845 shares were traded during trading, a decline of 84% from the average daily volume of 14,997,717 shares. The stock had previously closed at $0.2330.
Matinas Biopharma Stock Performance
The firm has a market capitalization of $1.50 million, a price-to-earnings ratio of -0.20 and a beta of 1.76. The company has a 50 day moving average price of $0.49 and a two-hundred day moving average price of $0.57.
Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC bought a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma at the end of the most recent reporting period. 11.77% of the stock is owned by institutional investors.
Matinas Biopharma Company Profile
Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.
The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.